Skip to main content

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology

Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Chase Doyle
Read More
In the Literature, Oncology
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR
Read More
In the Literature, Gastroenterology, Oncology
Sitagliptin, DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
Read More
Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Chase Doyle
Read More
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
Phoebe Starr
Read More
Cholangiocarcinoma, Oncology
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Read More
Cholangiocarcinoma, Oncology
Targeted Therapies in Cholangiocarcinoma
Read More
Leukemia, Oncology
Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Leukemia, Oncology
Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy
Wayne Kuznar
Read More
Page 1 of 3
Results 1 - 10 of 27